Do gel injections actually work?

Hyaluronic acid goes by several names — viscosupplementation, gel injections, and a list of brand names. It is a naturally occurring component of joint fluid, and the original rationale was mechanical: arthritic joint fluid is thinner than healthy fluid, so replacing it should restore cushioning and lubrication.

That mechanism is now considered incomplete. The injected material does not persist in the joint anywhere near as long as the reported benefit, which suggests any effect is more likely biological than mechanical. Worth knowing, because the lubrication story is still how it is usually sold.

What does the evidence actually show?

A meta-analysis of randomised trials against placebo, pooling 3,851 patients, found a pattern that is easy to report selectively and harder to summarise honestly.

The authors' own conclusion was appropriately cautious: hyaluronic acid might reduce pain in the short term. Not that it does not work — that the signal is real on some measures and absent on others, which is what a small true effect looks like when it is measured many ways.

Network meta-analyses comparing injectables against each other put it in a similar place. One pooling 79 trials and 8,761 patients found high-molecular-weight hyaluronic acid combined with corticosteroid ranked highest for function at four to six weeks and three months. Another, pooling 35 studies and 3,104 patients, ranked it above placebo and below platelet-rich plasma — and found no increase in treatment-related adverse events for any of the injectables studied.

Why do clinicians disagree about it?

Because a small, inconsistent effect is genuinely ambiguous, and there is no neutral way to weigh it.

One clinician reads "significant on two of five measures at four weeks" as a real but modest benefit worth offering. Another reads the same result as noise dressed up by multiple comparisons. Both are looking at the same table. The disagreement is about how much evidence a treatment needs before it earns a place, not about what the evidence says.

Cost sharpens it. Hyaluronic acid is substantially more expensive than corticosteroid and usually requires a course of injections rather than one. A modest benefit is easier to justify when it is cheap and harder when it is not — which is why coverage policies have tightened and why patients increasingly encounter it as a prior-authorisation problem rather than a clinical choice.

How does it compare to a cortisone shot?

Different shapes of benefit, and the comparison is more useful than a ranking — all three options are set side by side here.

Corticosteroid tends to work faster and harder early — the pooled data show a moderate effect at one to two weeks that decays to nothing detectable by six months. Hyaluronic acid is generally described as slower to take effect and, in some analyses, longer-lasting once it does. It is also considerably more expensive and usually given as a series.

For a joint that is acutely inflamed and needs relief this week, corticosteroid is the more predictable choice. For someone trying to avoid repeated steroid exposure, hyaluronic acid is a defensible thing to try, with realistic expectations set first.

Who it is most reasonable for

• Mild to moderate arthritis rather than end-stage. As with steroid, a joint that has run out of cartilage has less for any injection to work with.
• Someone who responds to corticosteroid but wants fewer of them — the frequency question is a real one, and this is one way people approach it.
• Diabetes that is difficult to control. Hyaluronic acid does not raise blood glucose the way corticosteroid does, which is a genuine practical advantage.
• Someone for whom the cost is manageable and who understands they are buying a modest chance of modest benefit.

It is least reasonable as a first move in someone who has not tried strengthening, load management, or anything else — for the same reason that applies to every injection on this site.